Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression

Objective The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). Methods A keyword-based literature search was conducted, and 26 publications were included. Results Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. Conclusions Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE.

[1]  C. Inderjeeth,et al.  Systemic lupus erythematosus: Reducing life-threatening progression , 2018 .

[2]  F. Pieruzzi,et al.  Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis , 2018, Annals of the rheumatic diseases.

[3]  M. Sheaff,et al.  Utility of a repeat renal biopsy in lupus nephritis: a single centre experience , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  M. Momtaz,et al.  Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience , 2017, Lupus.

[5]  J. Nolla,et al.  The value of repeat biopsy in lupus nephritis flares , 2017, Medicine.

[6]  Ron Wolterbeek,et al.  Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[7]  B. Rovin,et al.  Update on Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[8]  A. Sawalha,et al.  Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies , 2017, Current Rheumatology Reports.

[9]  J. Yazdany,et al.  Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. , 2017, Autoimmunity reviews.

[10]  I. Okpechi,et al.  Clinico-pathological features of repeat renal biopsies in patients with lupus nephritis at Groote Schuur Hospital, Cape Town , 2017, Lupus.

[11]  D. Isenberg,et al.  Off-label use of rituximab for systemic lupus erythematosus in Europe , 2016, Lupus Science & Medicine.

[12]  M. Ward,et al.  Risk of End‐Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta‐Analysis , 2016, Arthritis & rheumatology.

[13]  J. Andreu,et al.  Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER) , 2016, Medicine.

[14]  C. Gordon,et al.  Incidence of End‐Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry , 2016, Arthritis care & research.

[15]  A. Davidson What is damaging the kidney in lupus nephritis? , 2016, Nature Reviews Rheumatology.

[16]  Caroline Gordon,et al.  The frequency and outcome of lupus nephritis: results from an international inception cohort study. , 2016, Rheumatology.

[17]  J. Craig,et al.  Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines , 2015, Arthritis care & research.

[18]  J. Branco,et al.  Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real‐Life, International Systemic Lupus Erythematosus Cohort , 2015, Arthritis care & research.

[19]  Matthias Schneider,et al.  The Diagnosis and Treatment of Systemic Lupus Erythematosus. , 2015, Deutsches Arzteblatt international.

[20]  S. Quaglini,et al.  The Value of a Panel of Autoantibodies for Predicting the Activity of Lupus Nephritis at Time of Renal Biopsy , 2015, Journal of immunology research.

[21]  Lichuan Yang,et al.  Clinicopathological and outcome analysis of adult lupus nephritis patients in China , 2015, International Urology and Nephrology.

[22]  A. Ensari,et al.  Classifying Lupus Nephritis: An Ongoing Story , 2014, TheScientificWorldJournal.

[23]  Hannah Beckwith,et al.  Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis , 2014, Nephron Clinical Practice.

[24]  I. Gunnarsson,et al.  Role of early repeated renal biopsies in lupus nephritis , 2014, Lupus Science & Medicine.

[25]  E. Soriano,et al.  Value of repeat biopsy in lupus nephritis flares , 2014, Lupus Science & Medicine.

[26]  M. Jadoul,et al.  Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort , 2014, Lupus.

[27]  C. Putterman,et al.  Improving Outcomes in Patients with Lupus and End‐Stage Renal Disease , 2013, Seminars in dialysis.

[28]  S. Quaglini,et al.  Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years , 2013, Lupus.

[29]  P. Gaffney,et al.  Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. , 2011, Arthritis and rheumatism.

[30]  C. Vrabie,et al.  Manifestations of systemic lupus erythematosus. , 2011, Maedica.

[31]  D. Isenberg,et al.  Assessment of a lupus nephritis cohort over a 30-year period. , 2011, Rheumatology.

[32]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[33]  A. Darnell,et al.  Outcomes in Biopsy-Proven Lupus Nephritis: Evaluation of 190 White Patients From a Single Center , 2010, Medicine.

[34]  C. Gordon,et al.  Contemporary treatment of systemic lupus erythematosus: an update for clinicians , 2010, Therapeutic advances in chronic disease.

[35]  L. Nyström,et al.  Cumulative Risk, Age at Onset, and Sex-Specific Differences for Developing End-Stage Renal Disease in Young Patients With Type 1 Diabetes , 2010, Diabetes.

[36]  C. Mok Biomarkers for Lupus Nephritis: A Critical Appraisal , 2010, Journal of biomedicine & biotechnology.

[37]  A. S. Al Arfaj,et al.  Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia , 2009, Rheumatology International.

[38]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[39]  D. Isenberg,et al.  An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. , 2006, Rheumatology.

[40]  Yasunori Iwata,et al.  The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. , 2004, Kidney international.

[41]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[42]  V. D’Agati,et al.  Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  R. Cervera,et al.  The epidemiology of systemic lupus erythematosus , 2003, Clinical reviews in allergy & immunology.

[44]  D. Adu,et al.  Powerful morphometric indicator of prognosis in lupus nephritis. , 2003, QJM : monthly journal of the Association of Physicians.

[45]  J. Piette,et al.  Factors affecting outcome and prognosis in membranous lupus nephropathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  C. Lau,et al.  Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  J. Piette,et al.  Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. , 1999, Medicine.

[48]  M. Petri,et al.  A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. , 1997, Arthritis and rheumatism.

[49]  Mercedes A García,et al.  Long-term Outcome of Lupus Nephritis Class II in Argentine Patients An Open Retrospective Analysis , 2016 .